-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

902.O2.6 902. Health Services and Quality Improvement: Lymphoid Malignancies: For a Brighter Tomorrow - Improving Safety of Treatments

Symposia: Health Services and Quality Improvement: Lymphoid Malignancies Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Adult, Acute Myeloid Malignancies, Clinical trials, Clinical Practice (Health Services and Quality), Lymphomas, Elderly, Non-Hodgkin lymphoma, Clinical Research, Health outcomes research, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Patient-reported outcomes, Diseases, Real-world evidence, Clinical procedures, Aggressive lymphoma, Biological therapies, Treatment Considerations, Lymphoid Malignancies, Adverse Events, Survivorship, Emerging technologies, Technology and Procedures, Study Population, Human, Imaging, Pathology
Saturday, December 7, 2024: 4:00 PM-5:30 PM
Room 6B (San Diego Convention Center)
Moderators:
Muhammad Saad Hamid, MD, University of Tennessee Health Science Center and Abi Vijenthira, MD, SM, Princess Margaret Cancer Centre
Disclosures:
No relevant conflicts of interest to declare.
4:00 PM

Bryony Dawkins, MSc1*, Georgios Gkountouras, PhD2*, David Meads, PhD1*, Charlotte Pawlyn, PhD3, Kara-Louise Royle4*, Ethan R Senior5*, Dax Everritt5*, Jenny Bird6*, Stella Bowcock7,8*, Mark Drayson9*, Sharon Gillson, BSc5*, Catherine Olivier10*, Matthew W. Jenner11*, John R Jones12,13,14*, Martin F Kaiser, MD15, Bhuvan Kishore16*, Neil Rabin17*, Roger G Owen, MD, MRCP, FRCPath18*, Ruth M de Tute, MSc, PhD, FRCPath18*, Christopher Parrish, MBBChir, MRCP, FRCPath, MA, PhD4,19, David A. Cairns, PhD10*, Alan Chant20*, Graham Jackson, MD21* and Gordon Cook, PhD, DSc4,19*

1University of Leeds, Academic Unit of Health Economics, Leeds, United Kingdom
2Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, United Kingdom
3Institute of Cancer Research, Sutton, United Kingdom
4Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom
5Leeds Institute of Clinical Trials Research, Cancer Research UK Clinical Trials Unit, Leeds, United Kingdom
6Department of Haematology, University Hospitals Bristol NHS Foundation Trust, Cambridge, GBR
7Queen Mary's Sidcup NHS Trust, Sidcup, GBR
8King’s College Hospital, London, United Kingdom
9University of Birmingham, Institute of Immunology and Immunotherapy, Birmingham, United Kingdom
10Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom
11University Hospital Southampton, Southampton, United Kingdom
12Kings College Hospital, London, United Kingdom
13Brighton and Sussex Medical School, Brighton, United Kingdom
14East Sussex NHS Trust, Eastbourne, United Kingdom
15The Institute of Cancer Research, London, ENG, United Kingdom
16Heartofengland NHS FT, Birmingham, GBR
17Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom
18HMDS, Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
19Leeds Teaching Hospitals NHS Trust, Leeds Cancer Centre, Leeds, United Kingdom
20Patient and Public Contributor, NA, United Kingdom
21University of Newcastle, Department of Haematology, Newcastle, United Kingdom

4:15 PM

Dasom Lee, MD1, Sushma Bharadwaj, MD2, Masooma S Rana, MBBS3*, Alexandria Jensen4*, William Wang5*, Nima Ghalehsari, MD2, Bita Sahaf5*, Jayasindhu Mallampet5*, Sarah Elkordy5*, Theresa Latchford5*, Sally Arai, MD5, Laura Johnston, MD5, Hitomi Hosoya, MD, PhD2, Robert Lowsky, MD5*, Robert S. Negrin, MD5, Andrew R. Rezvani5*, Judith Shizuru5*, Everett H. Meyer, MD, PhD6, Parveen Shiraz5*, Lekha Mikkilineni, MD, MA2, Wen-Kai Weng, MD, PhD2, Lauren S. Maeda7*, Melody Smith, MD, MS6, Surbhi Sidana, MD6, Lori Muffly, MD6, Matthew J. Frank5, David B. Miklos, MD, PhD2 and Saurabh Dahiya, MD, FACP5*

1Department of Medicine, Division of Oncology, Stanford University, Redwood City, CA
2Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Palo Alto, CA
3Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Santa Clara, CA
4Quantitative Sciences Unit, Stanford University, Stanford, CA
5Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA
6Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA
7Department of Medicine, Division of Oncology, Stanford University, Stanford, CA

4:30 PM

Jonas Paludo, MD1, Amylou C Dueck, PhD2, Vishal Bhatnagar, MD3*, Abbie Y Brown4*, Elizabeth J Cathcart-Rake, MD5*, Devin B Copley1*, Matthew Diamond, MD, PhD3*, Louis J Faust, Ph.D.6*, Mallorie Fiero, PhD3*, Scott F Huntington7,8, Molly M Jeffery, Ph.D.9,10*, Lee Jones11*, Brie N Noble, MS2*, Brad Power12*, Jessica D Ritchie, MPH, PMP13*, Joseph S Ross, MD, MHS13,14*, Kathryn J Ruddy, MD5*, Sarah E Schellhorn, MD14,15*, Michelle Tarver, MD, PhD3*, Lisa M Torre, MS, CCRP16*, William A. Wood, MD, MPH17, Cary P Gross, MD14,15*, Paul G Kluetz, MD3* and Gita Thanarajasingam, MD1

1Division of Hematology, Mayo Clinic, Rochester, MN
2Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, AZ
3US Food and Drug Administration, Silver Spring, MD
4Health Education and Content Services, Mayo Clinic, Rochester, MN
5Department of Oncology, Mayo Clinic, Rochester, MN
6Division of Health Care Delivery Research, Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN
7Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale School of Medicine, New Haven, CT
8Yale School of Medicine, New Haven, CT
9Division of Health Care Delivery Research, Mayo Clinic, Rochester, MN
10Department of Emergency Medicine, Mayo Clinic, Rochester, MN
11Patient Advocate, Arlington, VA
12Patient Advocate, CancerHacker Lab, Boston, MA
13Yale-New Haven Center for Outcomes Research and Evaluation (CORE), Yale School of Medicine, New Haven, CT
14Department of Internal Medicine, Yale School of Medicine, New Haven, CT
15Yale's Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale School of Medicine, New Haven, CT
16Yale Center for Clinical Investigation (YCCI), Yale School of Medicine, New Haven, CT
17Division of Hematology, University of North Carolina, Chapel Hill, NC

4:45 PM

Xinjie Jonathan Tang, MBBS1, Joanne Shu Xian Lee2*, Esther Hian Li Chan1,3*, Sanjay De Mel, BSc, FRCPath, MRCP4*, Yen-Lin Chee2,3*, Wee-Joo Chng3,4,5, Michelle Limei Poon1,3*, Shi Hui Clarice Choong1,3* and Melissa Gaik-Ming Ooi1,3*

1Department of Haematology-Oncology, National University Cancer Institute, National University Health System, Singapore, Singapore
2Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore
3Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
4Department of Haematology-Oncology, National University Cancer Institute, Singapore, National University Health System, Singapore, Singapore
5Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore

5:00 PM

Lauren N Scott1*, William Wesson, MD, MPH1,2, Pilar Thangwaritorn, BS3*, Raeef L Rahman, BS1, Forat Lutfi, MD4, Marc Hoffmann, MD5, Zahra Mahmoudjafari, PharmD6*, Muhammad Umair Mushtaq7,8, Al-Ola Abdallah, MD8,9, Sunil Abhyankar, MD7, Joseph P. McGuirk, DO4, Muhammad Mahdi Nashatizadeh, MD5* and Nausheen Ahmed, MD6,8

1School of Medicine, University of Kansas Medical Center, Kansas City, KS
2US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS
3University of Kansas, Lawrence, KS
4University of Kansas Medical Center, Westwood, KS
5University of Kansas Medical Center, Kansas City, KS
6Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS
7Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS
8US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS
9University of Kansas Cancer Center, Fairway, KS

5:15 PM

Michelle Wang, PharmD, PhD1*, Krishna V. Komanduri, MD1, Debajyoti Datta, MD, PhD1*, Ayan Patel, MS1*, Barbee Whitaker, PhD2*, Artur Belov, PhD2*, Benjamin Rubin, PhD1*, Rohit Vashisht, PhD1*, Rosa Rodriguez-Monguio, PhD1*, Pelin Cinar, MD, MS1,3*, Steven Anderson, PhD2* and Atul Butte, MD, PhD1*

1University of California, San Francisco, San Francisco, CA
2Food and Drug Administration, Silver Spring, MD
3Gilead Sciences, Foster City, CA

*signifies non-member of ASH